Dr. Reza Mehrazin, MD
Dr. Reza Mehrazin is an attending at Mount Sinai School of Medicine. He has completed a two-year Society of Urologic Oncology (SUO) accredited fellowship at a highly prestigious National Cancer Institute (NCI) designated cancer center, Fox Chase Cancer Center. Dr. Mehrazin’s clinical expertise is in Robotic surgery, laparoscopic, and open surgical techniques for the treatment of various urologic cancers, which allows him to tailor a specific treatment plan based on individual patient need and preferences. He is one of the few urologists in the region who has extensive training and certified in performing minimally invasive organ preserving and reconstructive techniques to preserve function and quality of life for patients with urologic malignancies. He performs both robotic (using da Vinci® technology) and open cystectomies with continent urinary diversion (new bladder), nephron-sparing (kidney preserving) partial nephrectomy, nerve-sparing prostatectomy, partial or total adrenalectomy, retroperitoneal lymph node dissection for testicular cancer, and endoscopic nephron-sparing management of patients with upper tract urothelial carcinomas. He has authored and co-authored over 200 scientific manuscripts, abstracts, and text book chapters.
Is this doctor in your insurance network?
- Mount Sinai Beth Israel - Petrie Division
- Mount Sinai Faculty Practice Associates
- The Mount Sinai Hospital
- American Board of Urology
Education and training
- Fox Chase Cancer Center, Fellowship in Urologic Oncology and Robotic Surgery
- Medical School - Medical University of the Americas – Nevis, Doctor of Medicine
- University of Tennessee, Internship in General Surgery
- University of Tennessee, Residency in Urology
- American Urological Association
Awards and publications
- Mehrazin R, Palazzi KL, Kopp RP, Colangelo CJ, Stroup SP, Masterson JH, Liss MA, Cohen SA, Jabaji R, Park SK, Patterson AL, L'Esperance JO, Derweesh IH.Impact of tumour morphology on renal function decline after partial nephrectomy. BJU Int. 2013 Jun;11
- Mehrazin R, Uzzo RG, Kutikov A, Ruth K, Tomaszewski JJ, Dulaimi E, Ginzberg S, Abbosh PH, Ito T, Corcoran AT, Chen DY, Smaldone MC, Al-Saleem T. Lymphopenia is an independent predictor of inferior outcome in papillary renal cell carcinoma. Urologic oncology 2014 Jul
- Reza Mehrazin & Robert Uzzo: Renal Cell Carcinoma, Localized (T1-T2). The Five Minute Urology Consult, 3rd edition.
Mount Sinai Doctors
Mount Sinai Doctors Faculty Practice
5 East 98th Street, 6th Floor
New York, NY 10029